Investigating specific bacterial resistance to AMPs by using a magainin I-resistant Escherichia coli model

Journal of Antibiotics

Volumn 67, Issue 10, 2014, Pages 681-687

  De Almeida, Keyla C ^a,b   Lima, Thais B ^a   Motta, Dielle O ^a   Silva, Osmar N ^a   Magalhães, Beatriz S ^a   Dias, Simoni C ^a   Franco, Octávio L ^a,b  

^a Centro de Analises Proteomicas e Bioquymicas Pos Graduacao emCiencias Genomicas e Biotecnologia Universidade Catolica de Brasylia   (Brazil)

^b UNIVERSITY OF BRASILIA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CECROPIN; MAGAININ 1; ANTIINFECTIVE AGENT; ANTIMICROBIAL CATIONIC PEPTIDE; MAGAININ 1 PEPTIDE, XENOPUS; XENOPUS PROTEIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; CROSS RESISTANCE; DRUG MECHANISM; ESCHERICHIA COLI; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; CHEMISTRY; CLASSIFICATION; DRUG EFFECTS; MASS SPECTROMETRY; MICROBIAL SENSITIVITY TEST;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; SUS;

ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; MICROBIAL SENSITIVITY TESTS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; XENOPUS PROTEINS;

EID: 84908513918     PISSN: 00218820     EISSN: 18811469     Source Type: Journal    
DOI: 10.1038/ja.2014.48     Document Type: Article

References (56)

1. Fischbach, M. A. & Walsh, C. T. Antibiotics for emerging pathogens. Science 325, 1089-1093 (2009).
2. Conly, J. M. Antimicrobial resistance programs in Canada 1995-2010. Antimicrob. Resist. Infect. Control 1, 10-15 (2012).
3. Rosenthal, V. D. Health-care-associated infections in developing countries. Lancet 377, 186-188 (2011).
4. Park, S. H. et al. Emergence of extended-spectrum b-lactamase-producing Escherichia coli as a cause of community-onset bacteremia in South Korea: risk factors and clinical outcomes. Microb. Drug Resist. 17, 537-544 (2011).
5. World Health Organization. Report on the Burden of Endemic Health Care-Associated Infection Worldwide (WHO, Geneva, Switzerland, 2011).
6. Karakoc, C., Tekin, R., Yesilbag, Z. & Cagatay, A. Risk factors for mortality in patients with nosocomial Gram-negative rod bacteremia. Eur. Rev. Med. Pharmacol. Sci. 17, 951-957 (2013).
7. Arias, C. A. & Murray, B. E. Antibiotic-resistant bugs in the 21st century-a clinical super-challenge. New Engl. J. Med. 360, 439-443 (2009).
8. Lima, T. B. et al. Bacterial resistance mechanism: what proteomics can elucidate. FASEB J. 27, 1291-1303 (2013).
9. Bocchinfuso, G., Bobone, S., Mazzuca, C., Palleschi, A. & Stella, L. Fluorescence spectroscopy and molecular dynamics simulations in studies on the mechanism of membrane destabilization by antimicrobial peptides. Cell. Mol. Life Sci. 68, 2281-2301 (2011).
10. Hancock, R. E. & Chapple, D. S. Peptide antibiotics. Antimicrob. Agents Chemother. 43, 1317-1323 (1999).
11. Candido, E. S. et al. Plant storage proteins with antimicrobial activity: novel insights into plant defense mechanisms. FASEB J. 25, 3290-3305 (2011).
12. Fulmer, P. A., Lundin, J. G. & Wynne, J. H. Development of antimicrobial peptides (AMPs) for use in self-decontaminating coatings. ACS Appl. Mater. Interfaces 4, 1266-1270 (2010).
13. Wiesner, J. & Vilcinskas, A. The ancient arm of the human immune system. Virulence 1, 440-464 (2010).
14. Huang, Y., Huang, J. & Chen, Y. Alpha-helical cationic antimicrobial peptides: relationships of structure and function. Protein Cell 1, 143-152 (2010).
15. Brogden, K. A. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat. Rev. Microbiol. 3, 238-250 (2005).
16. Splith, K. & Neundorf, I. Antimicrobial peptides with cell-penetrating peptide properties and vice versa. Eur. Biophys. J. 40, 387-397 (2011).
17. Nguyen, L. T., Haney, E. F. & Vogel, H. J. The expanding scope of antimicrobial peptide structures and their modes of action. Trends Biotechnol. 29, 464-472 (2011).
18. Pushpanathan, M., Gunasekaran, P. & Rajendhran, J. Antimicrobial peptides: versatile biological properties. Int. J. Pept. 13, 1-15 (2013).
19. Steinstraesser, L. et al. Innate defense regulator peptide 1018 in wound healing and wound infection. PLoS ONE 7, 1-7 (2012).
20. Pena, O. M. et al. Synthetic cationic peptide IDR-1018 modulates human macrophage differentiation. PLoS ONE 8, 1-10 (2013).
21. Steinstraesser, L., Kraneburg, U., Jacobsen, F. & Al-Benna, S. Host defense peptides and their antimicrobial-immunomodulatory duality. Immunobiology 216, 322-333 (2011).
22. Zasloff, M. Magainins, a class of antimicrobial peptides from Xenopus skin: isolation, characterization of two active forms and partial cDNA sequence of a precursor. Proc. Natl Acad. Sci. USA 84, 5449-5453 (1987).
23. Imura, Y., Choda, N. & Matsuzaki, K. Magainin 2 in action: distinct modes of membrane permeabilization in living bacterial and mammalian cells. Biophys. J. 95, 5757-5765 (2008).
24. Pranting, M., Negrea, A., Rhen, M. & Andersson, D. I. Mechanism and fitness costs of PR-39 resistance in Salmonella enterica serovar Typhimurium LT2. Antimicrob. Agents Chemother. 52, 2734-2741 (2008).
25. Maria-Neto, S. et al. Deciphering the magainin resistance process of Escherichia coli strains in light of the cytosolic proteome. Antimicrob. Agents Chemother. 56, 1714-1724 (2012).
26. Peng, X. Proteomic analysis of the sarcosine-insoluble outer membrane fraction of Pseudomonas aeruginosa responding to ampicillin, kanamycin and tetracycline resistance. J. Proteome Res. 4, 2257-2265 (2005).
27. Zautner, A. E. et al. Discrimination of multilocus sequence typing-based Campylobacter jejuni sub-groups by MALDI-TOF mass spectrometry. BMC Microbiol. 13, 247 (2013).
28. Mellmann, A. et al. High interlaboratory reproducibility of matrix-assisted laser desorption ionization-time of flight mass spectrometry-based species identification of nonfermenting bacteria. J. Clin. Microbiol. 47, 3732-3734 (2009).
29. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. 22nd informational supplement. CLSI document M100-S22. (CLSI, Wayne, PA, USA, 2012).
30. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically 9th edn. Approved standard. CLSI document M07-A9. (CLSI, Wayne, PA, USA, 2012).
31. Epand, R. F. et al. Dual mechanism of bacterial lethality for a cationic sequencerandom copolymer that mimics host-defense antimicrobial peptides. J. Mol. Biol. 379, 38-50 (2008).
32. Mckenna, M. The last resort: Health officials are watching in horror as bacteria become resistant to powerful carbapenem antibiotics-one of the last drugs on the shelf. Nature 499, 394-396 (2013).
33. Winstanley, T. & Courvalin, P. Expert systems in clinical microbiology. Clin. Microbiol. Rev. 24, 515-556 (2011).
34. Zbinden, A., Bö ttger, E. C., Bosshard, P. P. & Zbinden, R. Evaluation of the colorimetric Vitek 2 card for identification of Gram-negative nonfermentative rods: comparison to 16S rRNA gene sequencing. J. Clin. Microbiol. 45, 2270-2273 (2007).
35. Tan, K. E. et al. Prospective evaluation of a matrix-assisted laser desorption ionizationtime of flight mass spectrometry system in a hospital clinical microbiology laboratory for identification of bacteria and yeasts: a bench-by-bench study for assessing the impact on time to identification and cost-effectiveness. J. Clin. Microbiol. 50, 3301-3308 (2012).
36. Van Veen, S. Q., Claas, E. C. J. & Kuijper, E. J. High-throughput identification of bacteria and yeast by matrix-assisted laser desorption ionization-time of flight mass spectrometry in conventional medical microbiology laboratories. J. Clin. Microbiol. 48, 900-907 (2010).
37. Arnold, R. J. & Reilly, J. P. Observation of Escherichia coli ribosomal proteins and their posttranslational modifications by mass spectrometry. Anal. Biochem. 269, 105-112 (1999).
38. Muroi, M., Shima, K., Igarashi, M., Nakagawa, Y. & Tanamoto, K. Application of matrixassisted laser desorption ionization-time off light mass spectrometry for discrimination of laboratory-derived antibiotic-resistant bacteria. Biol. Pharm. Bull. 35, 1841-1845 (2012).
39. Malakhova, M. V. et al. MALDI-TOF mass-spectrometry in analysis of genetically determined resistance of Streptococcus pneumoniae to fluoroquinolones. Antibiotic Khimioter 52, 7-10 (2007).
40. Charyulu, E. M., Gnanamani, A. & Mandal, A. B. Identification and discrimination of merhicillin resistant Staphylococcus aureus strains isolated burn wound sites using PCR and authentication with MALDI-TOF-MS. Indian J. Microbiol. 52, 337-345 (2012).
41. Camara, J. E. & Hays, F. A. Discrimination between wild-type and ampicillin-resistant Escherichia coli by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Anal. Bioanal. Chem. 389, 1633-1638 (2007).
42. Kosciuczuk, E. M. et al. Cathelicidins: family of antimicrobial peptides. Mol. Biol. Rep. 39, 10957-10970 (2012).
43. Sang, Y. & Blecha, F. Porcine host defense peptides: expanding repertoire and functions. Dev. Comp. Immunol. 33, 334-343 (2009).
44. Steiner, H., Hultmark, D., Engstrom, A., Bennich, H. & Boman, H. G. Sequence and specificity of two antibacterial proteins involved in insect immunity. Nature 292, 246-248 (1981).
45. Lee, J. Y. et al. Antibacterial peptides from pig intestine: isolation of a mammalian cecropin. Proc. Natl Acad. Sci. USA 86, 9159-9162 (1989).
46. Epand, R. M. & Epand, R. F. Bacterial membrane lipids in the action of antimicrobial agents. J. Pept. Sci. 17, 298-305 (2011).
47. Strauss, J., Kadilak, A., Cronin, C., Mello, C. M. & Camesano, T. A. Binding, inactivation and adhesion forces between antimicrobial peptides cecropin P1 and pathogenic E. coli. Colloids Surf. B Biointerfaces 75, 156-164 (2010).
48. Zanetti, M., Storici, P., Tossi, A., Scocchi, M. & Gennaro, R. Molecular cloning and chemical synthesis of a novel antimicrobial peptide derived from pig myeloid cells. J. Biol. Chem. 269, 7855-7858 (1994).
49. Kim, J. Y., Park, S. C., Yoon, M. Y., Hahm, K. S. & Park, Y. C-terminal amidation of PMAP-23: translocation to the inner membrane of Gram-negative bacteria. Amino Acids 40, 183-195 (2011).
50. Pillai, A., Ueno, S., Zhang, H., Lee, J. M. & Kato, Y. Cecropin P1 and novel nematode cecropins: a bacteria-inducible antimicrobial peptide family in the nematode Ascaris suum. Biochem. J. 390, 207-214 (2005).
51. Agerberth, B. et al. Amino acids sequence of PR-39. Isolation from pig intestine of a new member of the family of proline-arginine-rich antibacterial peptides. Eur. J. Biochem. 202, 849-854 (1991).
52. Hennig-Pauka, I. et al. PR-39, a porcine host defense peptide, is prominent in mucosa and lymphatic tissue of the respiratory tract in healthy pigs and pigs infected with Actinobacillus pleuropneumoniaie. BMC Res. Notes 5, 539-545 (2012).
53. Boman, H. G., Agerberth, B. & Boman, A. Mechanisms of action on Escherichia coli of cecropin P1 and PR-39, two antibacterial peptides from pig intestine. Infect. Immun. 61, 2978-2984 (1993).
54. Arcidiacono, S., Soares, J. W., Meehan, A. M., Marek, P. & Kirby, R. Membrane permeability and antimicrobial kinetics of cecropin P1 against Escherichia coli. J. Pept. Sci. 15, 398-403 (2009).
55. Lohner, K. New strategies for novel antibiotics: peptides targeting bacterial cell membranes. Gen. Physiol. Biophys. 28, 105-116 (2009).
56. Amiche, M. & Galanth, C. Dermaseptins as models for the elucidation of membraneacting helical amphipathis antimicrobial peptides. Curr. Pharm. Biotechnol. 12, 1184-1193 (2011).